Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators aim to retrospectively explore the electronic medical records of all patients who were admitted to the Intensive Care Unit (ICU) of the UZ Brussels in the last 10 years (March 1st 2011- March 1st 2021) and who received prolonged sedation (>24h) with sevoflurane.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sevoflurane group | Patients that received sevoflurane while in ICU care. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sevoflurane | Drug | Sevoflurane administration to sedate the patient |
|
| Measure | Description | Time Frame |
|---|---|---|
| Nephrogenic Diabetes Insipidus prevalence | How many patients under sevoflurane sedation ultimately develop NDI? NDI confirmed by demonstrating the absence of a urine concentrating response to exogenous Arginine Vasopressine. | up to 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients that develop risk factors of NDI | Number of patients that develop risk factors (electrolyte disorder, urinary obstruction) for NDI. | up to 8 weeks |
| Amount of time patient was placed under sevoflurane sedation. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
all patients who were admitted to the Intensive Care Unit (ICU) of the UZ Brussels in the last 10 years (March 1st 2011- March 1st 2021) and who received prolonged sedation (>24h) with sevoflurane.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UZ Brussel | Jette | Brussels Capital | 1090 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018500 | Diabetes Insipidus, Nephrogenic |
| ID | Term |
|---|---|
| D003919 | Diabetes Insipidus |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077149 | Sevoflurane |
| ID | Term |
|---|---|
| D008738 | Methyl Ethers |
| D004987 | Ethers |
| D009930 | Organic Chemicals |
| D006845 | Hydrocarbons, Fluorinated |
Not provided
Not provided
Not provided
Not provided
Not provided
How long are they under sevoflurane sedation.
| up to 8 weeks |
| Number of patients with electrolyte abnormalities as assessed by lab results. | Lab results of hematology and chemistry labs show an electrolyte imbalance. | during hospitalization, up to 8 weeks. |
| Number of patients with excessive urine output | Amount of urine output: >40 ml/kg/24h | during hospitalization, up to 8 weeks. |
| Number of patients with an abnormal physical examination. | Typical physical symptoms of (N)DI: tired, lethargic, tachycardia, tachypnea, hypotension and dry mucous membranes. | during hospitalization, up to 8 weeks. |
| Number of patients with urine with an abnormal osmolality | Lab testing of urine: osmolality < 300 mosm/kg | during hospitalization, up to 8 weeks. |
| Number of patients that show an abnormal amount of fluid intake | >2.5l/day | during hospitalization, up to 8 weeks. |
| Number of patients that have an abnormal abdominal echo of the bladder. | Echo shows an enlarged bladder. | during hospitalization, up to 8 weeks. |
| Number of symptoms of NDI | Number of symptoms of NDI do these patients show? | up to 8 weeks |
| Timing of symptoms of NDI | After how much time do these patients show symptoms of NDI? | up to 8 weeks |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D006846 |
| Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |